

CURRICULUM VITAE

Name: Rukhsana R. Azam

Citizenship Status: United States Citizen

Place of Birth: Bettiah, Bihar, India

Mailing Address: Hematology & Medical Oncology
12901 Bruce B. Downs Blvd.
Tampa, FL 33612

Telephone: (813) 974-7074 (Work)

Education:

1960 – 1967 Degree: High School Diploma
St. Teresa Girls High School
Bettiah, Bihar, India

1967 – 1968 Degree: Pre-Science Degree
Patna Woman's College
Patna, Bihar, India

1968 – 1971 Degree: Intermediate Science Degree
M.J.K. College
Bihar University
Bettiah, Bihar, India

1971 – 1978 Medical Degree: Bachelor of Medicine
Degree and Bachelor of Surgery
Degree (MBBS)
Darbhanga Medical College
Lalit Narayan Mithla University
Darbhanga, Bihar, India

Training and Professional Experience

1978 – 1979 Resident Rotating Internship
Darbhanga Medical College
Bihar, India

1979 – 1980	Resident Housemanship Department of Obstetrics and Gynecology Darbhanga Medical College Bihar, India
1982 – 1998	Family Practitioner, General Medicine and Ob/Gyn Ministry of Health Al-Baha, Saudi Arabia
1998 – Present	Program Coordinator Comprehensive Adult Hemophilia Program Division of Hematology/Oncology University of South Florida College of Medicine Tampa, FL
1999 – 1999	HIV Intensive Training Program
1999-Present	Clinical Research Coordinator Division of Hematology/Oncology University of South Florida College of Medicine Tampa, FL

Clinical Research Coordinator Experience

1. Granulocyte Surface Adhesion Proteins: Clinical Correlation with Infection in MDS Patients
2. An Epidemiological Study of Immune Thrombocytopenic Purpura to Evaluate the Relationship Between Platelet Counts, Endogenous Thrombopoietin Level, Endogenous Anti-Thrombopoietin Antibodies and Selected Autoimmune Marker
3. CDC (Center for Disease Control) Universal Data Collection and Serum Collection System for Hemophilia
4. Study of Thrombosis in Lupus Anticoagulant Patients
5. The Effects of PROCRIT (Epoetin alfa) on Hemoglobin, Symptom Distress and Quality of Life During Chemotherapy in Lymphoma, Chronic

Lymphocytic Leukemia or Multiple Myeloma Patients with Mild to Moderate Anemia

6. An Open-Label, Randomized Study to Develop a Screening Tool for Functional Capacity in Anemic Subjects with Nonmyeloid Malignancies Receiving Chemotherapy and Darbepoetin Alfa (NESP)
7. A Randomized, Open-Label, Phase III Trial of Decitabine (5-Aza-2'-deoxycytidine) Versus Supportive Care in Adults With Advanced-Stage Myelodysplastic Syndrome (SGI-DAC-0007)
8. An Open-Label Phase II Trial of Low-Dose Decitabine (5-aza-2'-deoxycytidine) in Patients with Acute Myeloid Leukemia (AML) Following Myelodysplastic Syndrome (A Companion Study to D-0007)
9. CAM307-A2: A Phase III Study to Evaluate the Efficacy and Safety of Front-line Therapy with Alemtuzumab (Campath®, MabCampath™) vs. Chlorambucil in Patients with Progressive B-Cell Chronic Lymphocytic Leukemia
10. A Phase 2, Multicenter, Open Label Study of the Safety and Efficacy of High-Dose Pulse Administration DN-101 (Calcitriol) in Patients with Myelodysplastic Syndrome
11. An Open-Label, Prospective, Stratified, Randomized, Controlled Multi-Center, Phase IIB Study Of the Impact of Thymoglobulin® Therapy on Transfusion Needs of Patients With Early Myelodysplastic Syndrome (MDS) (SMC 101-1020)
12. A Study of Darbepoetin Alfa in Anemic Subjects With Low Risk Myelodysplastic Syndrome
13. Advate Pass: A Post Authorization Safety Surveillance study of Advate rAHF-PFM in Hemophilia A Patients
14. A randomized, open-label, multi-center, phase II study to evaluate the safety and efficacy of oral ICL670 (deferiasirox) 20mg/kg/day relative to subcutaneous deferoxamine in sickle cell disease patients with iron overload from repeated blood transfusions.
15. A Phase III Randomized Study of CLORETAZINE TM (VNP 40101M) and Cytocine Atabinoside (AraC) in Patients with Acute Myeloid Leukemia in First Relapse – CLI-037

16. A Worldwide, Observational Registry collecting Longitudinal Data on the management of Chronic Myelogenous Leukemia (CML) patients (The WORLD CML Registry) in routine practice
17. Phase II study to evaluate efficacy and safety of single weekly administration of Bortezomib in newly diagnosed multiple myeloma
18. An Open-label, Multicenter Evaluation of the Safety, Pharmacokinetics, and Efficacy of Recombinant Factor VIII Fc Fusion Protein (rFVIII-Fc) in the Prevention and Treatment of Bleeding in Previously Treated Subjects with Severe Hemophilia A Protocol No 997HA301
19. Study of Prophylaxis, activity and effectiveness (SPACE) in Hemophilia patients currently treated with Advate or Rixubis. Quintiles and Baxter. Protocol No 061302
20. The American Thrombosis and Hemostasis Network (ATHN) database initiation to assess the tools, supplies, Intel, and training requirements that HTC staff need to provide service for their patients.

Clinical Experience

I currently serve as a primary liaison between the Hematology/Thrombosis and Hemophilia Treatment Center at the University of South Florida and other services such as the USF Internal Medicine, other USF clinics and the Tampa General Hospital. Receive incoming staff calls, patients, and visitors, independently triaging the nature the call/visit, determining which can be taken care of personally, which must be directed to the doctor, and which should be referred elsewhere. Keep the appointment calendar of the clinics. Organize and maintain patient files and records, including any correspondence received. Enter electronically any patient results or notes as indicated. Print laboratory results, review them and determine any abnormal results. Reports to the doctor any lab results that are abnormal. Work independently and collaboratively as needed, exercise good judgment concerning administrative procedures, and organize work schedule to maximize efficiency. I work in the clinics directly with patients and assist the doctor in obtaining any information regarding the patient's well-being at the time of visit, lab results, pharmacy requests, or phone calls. I make frequent contact with professional and nonprofessional employees, both supervisory and nonsupervisory. Contacts are with patients and their families, co-workers, house staff, medical students, Chiefs of Services, secretaries, etc. I also protect all printed and electronic files containing sensitive and confidential data.

Publications

1. Saba HI, Tannenbaum B, Morelli G, **Azam R**, Atanes I, Nichols C. Prophylaxis in Adult Hemophiliacs. *Blood*, 92 (10, S1): 109b, 1998.
2. Saba HI, **Azam R**, Moscinski L. Clinical Correlation of Infection in Myelodysplastic Syndrome Patients with Granulocyte Surface Adhesion Proteins. *Blood*, 94 (10, S1):110a 1999.
3. Saba HI, **Azam R**, Morelli G, Agosti S, Foulis P. Lupus Anticoagulant: An Analysis of 50 Patients for Their Course and Complications. *Blood*, 94 (10, S1):112b, 1999.
4. Saba HI, Morelli GA, Letson GD, **Azam R**, Klein C. Efficacy of Activated Factor VII (NovoSeven®) in Surgery on a Hemophilia Patient with a History of Inhibitor. *Blood*, 98 (11): 3964, 2001.
5. Saba HI, Morelli GA, **Azam RR**, Klein CJ, Letson GD. Efficacy of NovoSeven® during surgery on a hemophiliac with Previous History of Inhibitors. *Hemophilia* 2003, 9(1): 131-136.